Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 2
1996 6
1997 4
1998 4
1999 7
2000 7
2001 6
2002 4
2003 6
2004 2
2005 5
2006 6
2007 5
2008 11
2009 11
2010 6
2011 4
2012 5
2013 3
2014 6
2015 8
2017 1
2018 1
2021 2
2023 1
2024 2
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

120 results

Results by year

Filters applied: . Clear all
Page 1
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
Hutchings M, Morschhauser F, Iacoboni G, Carlo-Stella C, Offner FC, Sureda A, Salles G, Martínez-Lopez J, Crump M, Thomas DN, Morcos PN, Ferlini C, Bröske AE, Belousov A, Bacac M, Dimier N, Carlile DJ, Lundberg L, Perez-Callejo D, Umaña P, Moore T, Weisser M, Dickinson MJ. Hutchings M, et al. Among authors: ferlini c. J Clin Oncol. 2021 Jun 20;39(18):1959-1970. doi: 10.1200/JCO.20.03175. Epub 2021 Mar 19. J Clin Oncol. 2021. PMID: 33739857 Free PMC article. Clinical Trial.
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Lenihan D, Onofrei C, Shannon V, Sharma R, Silk AW, Skondra D, Suarez-Almazor ME, Wang Y, Wiley K, Kaufman HL, Ernstoff MS; Society for Immunotherapy of Cancer Toxicity Management Working Group. Puzanov I, et al. J Immunother Cancer. 2017 Nov 21;5(1):95. doi: 10.1186/s40425-017-0300-z. J Immunother Cancer. 2017. PMID: 29162153 Free PMC article.
From Protein Communication to Drug Discovery.
Persico M, Di Dato A, Orteca N, Fattorusso C, Novellino E, Andreoli M, Ferlini C. Persico M, et al. Among authors: ferlini c. Curr Top Med Chem. 2015;15(20):2019-31. doi: 10.2174/1568026615666150519102257. Curr Top Med Chem. 2015. PMID: 25986690 Review.
Class III β-tubulin in normal and cancer tissues.
Mariani M, Karki R, Spennato M, Pandya D, He S, Andreoli M, Fiedler P, Ferlini C. Mariani M, et al. Among authors: ferlini c. Gene. 2015 Jun 1;563(2):109-14. doi: 10.1016/j.gene.2015.03.061. Epub 2015 Apr 1. Gene. 2015. PMID: 25839941 Free PMC article. Review.
Tumor flare with T-cell-engaging bispecific antibodies.
Carlo-Stella C, Dickinson MJ, Iacoboni G, Carpio C, Dimier N, Weisser M, Kwan A, Ferlini C. Carlo-Stella C, et al. Among authors: ferlini c. Leuk Lymphoma. 2024 Oct;65(10):1524-1527. doi: 10.1080/10428194.2024.2361100. Epub 2024 Jun 5. Leuk Lymphoma. 2024. PMID: 38836333 No abstract available.
Novel drugs targeting microtubules: the role of epothilones.
Ferrandina G, Mariani M, Andreoli M, Shahabi S, Scambia G, Ferlini C. Ferrandina G, et al. Among authors: ferlini c. Curr Pharm Des. 2012;18(19):2793-803. doi: 10.2174/138161212800626238. Curr Pharm Des. 2012. PMID: 22390763 Review.
βIII-Tubulin: biomarker of taxane resistance or drug target?
Karki R, Mariani M, Andreoli M, He S, Scambia G, Shahabi S, Ferlini C. Karki R, et al. Among authors: ferlini c. Expert Opin Ther Targets. 2013 Apr;17(4):461-72. doi: 10.1517/14728222.2013.766170. Epub 2013 Feb 2. Expert Opin Ther Targets. 2013. PMID: 23379899 Review.
120 results